MediciNova Inc. (NASDAQ:MNOV) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows us MediciNova Inc. and Brainstorm Cell Therapeutics Inc.s net margins, return on assets and return on equity.

Risk and Volatility

A beta of 1.18 shows that MediciNova Inc. is 18.00% more volatile than Standard and Poors 500. Brainstorm Cell Therapeutics Inc. has a 1.19 beta and it is 19.00% more volatile than Standard and Poors 500.

Liquidity

The Current Ratio and Quick Ratio of MediciNova Inc. are 34.8 and 34.8 respectively. Its competitor Brainstorm Cell Therapeutics Inc.s Current Ratio is 1 and its Quick Ratio is 1. MediciNova Inc. can pay off short and long-term obligations better than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for MediciNova Inc. and Brainstorm Cell Therapeutics Inc.

Meanwhile, Brainstorm Cell Therapeutics Inc.s consensus price target is $9, while its potential upside is 127.85%.

Institutional and Insider Ownership

Roughly 21.3% of MediciNova Inc. shares are owned by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. About 2.7% of MediciNova Inc.s share are owned by insiders. Competitively, 0.6% are Brainstorm Cell Therapeutics Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year MediciNova Inc.s stock price has bigger growth than Brainstorm Cell Therapeutics Inc.

Summary

MediciNova Inc. beats on 7 of the 11 factors Brainstorm Cell Therapeutics Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The companys product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a 2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Original post:
Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly